Social determinants of health associated with hepatitis C co-infection among people living with HIV: Results from the Positive Spaces, Healthy Places study

Open Medicine

Volumn 5, Issue 3, 2011, Pages 120-131

  Rourke, Sean B ^a,b,c,d   Sobota, Michael ^e   Tucker, Ruthann ^a   Bekele, Tsegaye ^a   Gibson, Katherine ^e   Greene, Saara ^f   Price, Colleen ^g   Jay Koornstra, J J ^h   Monette, LaVerne ⁱ   Byers, Steve ^j   Watson, James ^a   Hwang, Stephen W ^d,k,l   Guenter, Dale ^f   Dunn, James ^d,f   Ahluwalia, Amrita ^m   Wilson, Michael G ^a   Bacon, Jean ^a  

^a ONTARIO HIV TREATMENT NETWORK   (Canada)

^b Universities Without Walls   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e AIDS Thunder Bay   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g Canadian Treatment Action Council (CTAC) HIV and Hepatitis Working Group   (Canada)

^h Bruce House   (Canada)

ⁱ Ontario Aboriginal HIV/AIDS Strategy   (Canada)

^j AIDS Niagara   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l ST MICHAEL'S HOSPITAL   (Canada)

^m Fife House   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80055048165     PISSN: None     EISSN: 19112092     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr PE, Bucher HC, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005;41(3):395-402.
2. Hershow R, Kalish L, Sha B, Till M, Cohen M. Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission. Sex Transm Dis 1998;25(10):527-532.
3. Jones R, Dunning J, Nelson M. HIV and hepatitis C co-infection. Int J Clin Pract 2005;59(9):1082-1087.
4. Remis R. Final report: Estimating the number of persons co-infected with hepatitis C virus and human immunodeficiency virus in Canada. Ottawa: Population and Public Health Branch, Health Canada; 2001. Available from: www.phac-aspc.gc.ca/hepc/pubs/hivhcvvhcvih/pdf/hivhcvreport_e.pdf (accessed 2010 August 23).
5. Public Health Agency of Canada. Epidemiology of acute hepatitis C infection in Canada: results from the Enhanced Hepatitis Strain Surveillance System (EHSSS). 2009. Available from: www.phacaspc.gc.ca/sti-its-surv-epi/pdf/hcv-epi-eng.pdf (accessed 2010 August 23).
6. Blanchette V, Walker I, Gill P, Adams M, Roberts R, Inwood M. Hepatitis C infection in patients with hemophilia: results of a national survey. Canadian Hemophilia Clinic Directors Group. Tranfus Med Rev 1994;8(3):210-217.
7. Frederick T, Burian P, Terrault N, Cohen M, Augenbraun M, Young M, et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDs 2009;23(11):915-923.
8. Tortu S, McMahon JM, Pouget ER, Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst Use Misuse 2004;39(2):211-224.
9. Howe CJ, Fuller CM, Ompad DC, Galea S, Koblin B, Thomas D, et al. Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City. Drug Alcohol Depend 2005;79(3):389-395.
10. Roy KM, Goldberg DJ, Hutchinson S, Cameron SO, Wilson K, MacDonald L. Hepatitis C virus among self declared noninjecting sexual partners of injecting drug users. J Med Virol 2004;74(1):62-66.
11. Fischer B, Powis J, Firestone Cruz M, Rudzinski K, Rehm J. Hepatitis C virus transmission among oral crack users: viral detection on crack paraphernalia. Eur J Gastroenterol Hepatol 2008;20(1):29-32.
12. Vertical transmission of the hepatitis C virus: Current knowledge and issues. Paediatr Child Health 2008;13(6):529-534.
13. Schnuriger A, Dominguez S, Guiguet M, Harfouch S, Samri A, Ouazene Z, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 2009;23(16):2079-2089.
14. Capa L, Soriano V, García-Samaniego J, Nuñez M, Romero M, Cascajero A, et al. Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4+ and CD8+ T-cell responses to hepatitis C virus. J Med Virol 2007;79(5):503-510.
15. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30(4):1054-1058.
16. Osinusi A, Kleiner D, Wood B, Polis M, Masur H, Kottilil S. Rapid development of advanced liver fibrosis after acquisition of hepatitis C infection during primary HIV infection. AIDS Patient Care STDS 2009;23(6):403-406.
17. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection. Clin Infect Dis 2001;33(4):562-569.
18. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001;33(2):240-247.
19. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000;356(9244):1800-1805.
20. Tsui JI, Bangsberg DR, Ragland K, Hall CS, Riley ED. The impact of chronic hepatitis C on health-related quality of life in homeless and marginally housed individuals with HIV. AIDS Behav 2007;11(4):603-610.
21. Braitstein P, Li K, Kerr T, Montaner JS, Hogg RS, Wood E. Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone. AIDS Care 2006;18(7):690-693.
22. Raphael D. Social determinants of health: Canadian perspectives. Toronto: Canadian Scholars' Press; 2004.
23. Amin J, Kaye M, Skidmore S, Pillay D, Cooper DA, Dore GJ. HIV and hepatitis C coinfection within the CAESAR Study. HIV Med 2004;5(3):174-179.
24. Remis RS. The epidemiology of hepatitis C infection in Ontario, 2004 [presentation]. Toronto: Ontario Harm Reduction Distribution Program; 4-6 March 2007. Available from: www.phs.utoronto.ca/ohemu/doc/EpiHCVOnt.pdf.
25. Remis RS. Epidemiology of hepatitis C infection in Canada [presentation]. 1st Canadian Conference on Hepatitis C, Montreal (QC); 1-4 May 2001. Available from: www.phs.utoronto.ca/ohemu/doc/HepCrev4.ppt.
26. Public Health Agency of Canada. Enhanced surveillance of risk behaviours among injecting drug users in Canada. 2006. Available from: www.phac-aspc.gc.ca/i-track/sr-re-1/index-eng.php (accessed 2010 August 23).
27. Galea S, Vlahov D. Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep 2002;117(Suppl 1):S135-S145.
28. Freudenberg N. Adverse effects of US jail and prison policies on the health and well-being of women of color. Am J Public Health 2002;92(12):1895-1999.
29. Awofeso N. Prisons as social determinants of hepatitis C virus and tuberculosis infections. Public Health Rep 2010;125(Suppl 4):25-33.
30. Operskalski EA, Mack WJ, Strickler HD, French AL, Augenbraun M, Tien PC, et al. Factors associated with hepatitis C viremia in a large cohort of HIV-infected and-uninfected women. J Clin Virol 2008;41(4):255-263.
31. Nyamathi AM, Dixon EL, Robbins W, Smith C, Wiley D, Leake B, et al. Risk factors for hepatitis C virus infection among homeless adults. J Gen Intern Med 2002;17(2):134-143.
32. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34(6):831-837.
33. Kim C, Kerr T, Li K, Zhang R, Tyndall MW, Montaner JS, et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health 2009;9(1):270.
34. Hall CS, Charlebois ED, Hahn JA, Moss AR, Bangsberg DR. Hepatitis C virus infection in San Francisco's HIV-infected urban poor. J Gen Intern Med 2004;19(4):357-365.
35. Irwin A, Scali E. Action on the social determinants of health: learning from previous experiences. Background paper. Geneva: World Health Organization; 2005. Available from: www.who.int/social_determinants/resources/action_sd.pdf (accessed 2010 August 23).
36. Aidala AA, Sumartojo E. Why housing? AIDS Behav 2007;11(6 Suppl):1-6.
37. Corneil TA, Kuyper LM, Shoveller J, Hogg RS, Li K, Spittal PM, et al. Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users. Health Place 2006;12(1):79-85.
38. Sumartojo E. Structural factors in HIV prevention: concepts, examples, and implications for research. AIDS 2000;14:Suppl 1:S3-S10.
39. Minkler M, Wallerstein N, editors. Community-based participatory research for health. San Francisco: Jossey-Bass; 2003.
40. Joint United Nations Programme on HIV and AIDS. The Greater Involvement of People Living with HIV (GIPA). 2007. Available from: http://whqlibdoc.who.int/unaids/2007/policybrief_gipa_eng.pdf.
41. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997;6(6):481-493.
42. Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care 1998;36(2):126-37.
43. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1977;1(3):385-401.
44. Devins GM, Orme CM, Costello CG, Binik YM, Frizzell B, Starn HJ, et al. Measuring depressive symptoms in illness populations: psychometric properties of the Center for Epidemiologic Studies Depression (CES-D) scale. Psychol Health 1988;2(2):139-156.
45. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The Alcohol Use Disorders Identification Test (AUDIT). 2nd ed. Geneva: World Health Organization; 2001.
46. Fleming MF, Barry KL, MacDonald R. The alcohol use disorders identification test (AUDIT) in a college sample. Int J Addict 1991;26(11):1173-1185.
47. Hays RD, Merz JF, Nicholas R. Response burden, reliability, and validity of the CAGE, Short MAST, and AUDIT alcohol screening measures. Behav Res Methods Instrum Comput 1995;27(2):277-280.
48. Skinner HA. The drug abuse screening test. Addict Behav 1982;7(4):363-371.
49. Cocco KM, Carey KB. Psychometric properties of the Drug Abuse Screening Test in psychiatric outpatients. Psychol Assess 1998;10(4):408-14.
50. Saltstone R, Halliwell S, Hayslip MA. A multivariate evaluation of the Michigan Alcoholism Screening Test and the Drug Abuse Screening Test in a female offender population. Addict Behav 1994;19(5):455-462.
51. Dunn JR, Hayes MV. Social inequality, population health, and housing: a study of two Vancouver neighborhoods. Soc Sci Med 2000;51(4):563-587.
52. Greenland S. Principles of multilevel modelling. Int J Epidemiol 2000;29(1):158-167.
53. Diez-Roux AV. Multilevel analysis in public health research. Annu Rev Public Health 2000;21(1):171-192.
54. Remis RS. Modelling the incidence and prevalence of hepatitis C infection and its sequelae in Canada, 2007. F inal r eport. O ttawa: Public Health Agency of Canada; 2009. Available from www.phac-aspc.gc.ca/sti-its-surv-epi/model/pdf/model07-eng.pdf (accessed 2011 June 26).
55. Ford PM, Pearson M, Sankar-Mistry P, Stevenson T, Bell D, Austin J. HIV, hepatitis C and risk behaviour in a Canadian mediumsecurity federal penitentiary. Queen's University HIV Prison Study Group. QJM 2000;93(2):113-119.
56. Holsen DS, Harthug S, Myrmel H. Prevalence of antibodies to hepatitis C virus and association with intravenous drug abuse and tattooing in a national prison in Norway. Eur J Clin Microbiol Infect Dis 1993;12(9):673-676.
57. Fox RK, Currie SL, Evans J, Wright TL, Tobler L, Phelps B, et al. Hepatitis C virus infection among prisoners in the California state correctional system. Clin Infect Dis 2005;41:177-186.
58. Wright NM, Tompkins CNE, Jones L. Exploring risk perception and behaviour of homeless injecting drug users diagnosed with hepatitis C. Health Soc Care Community 2005;13(1):75-83.
59. German D, Davey MA, Latkin CA. Residential transience and HIV risk behaviors among injection drug users. AIDS Behav 2007;11(6 Suppl):21-30.
60. Millson P, Myers T, Calzavara L, Wallace E, Major C, Degani N. Regional variation in HIV prevalence and risk behaviours in Ontario injection drug users (IDU). Can J Public Health 2003;94(6):431-435.
61. Remis R, Swantee C, Schiedel L, Liu J. Report on HIV/AIDS in Ontario 2006. Technical report. Toronto: Ontario Ministry of Health and Long-Term Care; 2008. Available from: www.phs.utoronto.ca/ohemu/doc/PHERO2006_report_final.pdf (accessed 2011 June 26).
62. Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS 2005;19 Suppl 2:S67-S72.
63. Williams P, Narciso L, Browne G, Roberts J, Weir R, Gafni A. Characteristics of people living with HIV who use communitybased services in Ontario, Canada: implications for service providers. J Assoc Nurses AIDS Care 2005;16(4):50-63.
64. Lo Re V 3rd, Frank I, Gross R, Synnestvedt M, Localio AR, Kostman JR, et al. Self-reported hepatitis B and C virus infections had low sensitivity among HIV-infected patients. J Clin Epidemiol 2007;60(3):294-299.